MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 113 filers reported holding MERSANA THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,641 | +89.2% | 17,040 | +390.1% | 0.00% | – |
| Q2 2023 | $11,441 | -99.8% | 3,477 | -99.6% | 0.00% | -100.0% |
| Q4 2021 | $5,089,000 | +1294.2% | 818,100 | +2941.3% | 0.02% | +900.0% |
| Q2 2021 | $365,000 | -97.8% | 26,900 | -97.4% | 0.00% | -97.5% |
| Q1 2021 | $16,877,000 | -31.2% | 1,043,100 | +13.1% | 0.08% | -34.2% |
| Q4 2020 | $24,534,000 | +26.2% | 922,000 | -11.7% | 0.12% | +20.0% |
| Q3 2020 | $19,438,000 | +2160.2% | 1,043,933 | +596.0% | 0.10% | +1900.0% |
| Q4 2019 | $860,000 | +10.0% | 150,000 | -69.7% | 0.01% | 0.0% |
| Q3 2019 | $782,000 | -71.0% | 495,000 | -25.6% | 0.01% | -64.3% |
| Q2 2019 | $2,693,000 | -66.6% | 665,000 | -56.7% | 0.01% | -62.2% |
| Q1 2019 | $8,071,000 | +259.7% | 1,534,370 | +179.0% | 0.04% | +236.4% |
| Q4 2018 | $2,244,000 | -11.4% | 550,000 | +287.8% | 0.01% | +10.0% |
| Q2 2018 | $2,533,000 | -5.5% | 141,808 | -16.6% | 0.01% | -9.1% |
| Q1 2018 | $2,681,000 | – | 170,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $40,026,000 | 4.69% |
| Opaleye Management Inc. | 1,047,000 | $4,837,000 | 2.18% |
| Sarissa Capital Management LP | 4,299,297 | $19,863,000 | 2.00% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $4,178,000 | 1.58% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 850,000 | $3,927,000 | 1.21% |
| Orbimed Advisors | 9,011,437 | $41,633,000 | 0.75% |
| Avoro Capital Advisors LLC | 7,550,000 | $34,881,000 | 0.69% |
| Rock Springs Capital Management LP | 4,075,958 | $18,831,000 | 0.55% |
| Artal Group S.A. | 2,200,000 | $10,164,000 | 0.54% |
| DAFNA Capital Management LLC | 406,763 | $1,879,000 | 0.51% |